Xilio Therapeutics (XLO) Preferred Stock Liabilities (2020 - 2021)

Xilio Therapeutics (XLO) has 2 years of Preferred Stock Liabilities data on file, last reported at $100.2 million in Q3 2021.

• For the quarter ending Q3 2021, Preferred Stock Liabilities rose 100.49% year-over-year to $100.2 million; the trailing twelve-month figure through Sep 2021 stood at $100.2 million (up 100.49% YoY), and the FY2020 full-year result was $7.3 million, changed N/A from the prior year.
• Preferred Stock Liabilities advanced to $100.2 million in Q3 2021, from $7.3 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $100.2 million in Q3 2021 to a low of $7.3 million in Q4 2020.